Dr. Luskin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215
Education & Training
Brigham and Women's HospitalChief Residency, Internal Medicine, 2015 - 2016
University of PennsylvaniaMSCE, Epidemiology, 2013 - 2015
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2012 - 2015- Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
Perelman School of Medicine at the University of PennsylvaniaClass of 2009
Certifications & Licensure
RI State Medical License 2022 - 2026
MA State Medical License 2009 - 2025
ME State Medical License 2022 - 2025
NH State Medical License 2023 - 2025
CT State Medical License 2022 - 2024
PA State Medical License 2012 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Start of enrollment: 2018 Jul 24
- Ruxolitinib in Thrombocythemia and Polycythemia Vera Start of enrollment: 2022 Mar 21
Roles: Contact, Principal Investigator
- Venetoclax Plus Inotuzumab for B-ALL Start of enrollment: 2021 Sep 24
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 59 citationsGenomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim Hien T. Dao, Emily A. Stevens
Blood. 2019-09-12 - 1 citationsSubunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun
Leukemia. 2024-09-01 - 81 citationsPrediction of risk for myeloid malignancy in clonal hematopoiesis.Lachelle D Weeks, Abhishek Niroula, Donna Neuberg, Waihay Wong, R Coleman Lindsley
NEJM Evidence. 2023-05-01
Abstracts/Posters
- Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative StudiesMarlise Luskin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Pre...Marlise Luskin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International CollaborationMarlise Luskin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Boston College Grad Celebrates ‘Double Graduation’ from School and Cancer TreatmentJune 6th, 2021- Ruxolitinib in Thrombocythemia and Polycythemia VeraNovember 25th, 2020
CML & Pregnancy: Patient & Partner ConsiderationsJune 5th, 2018- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
